ArticleInfection2025
Cervical Mycobacterium genavense infection in a patient with lymphadenitis and previously unknown anti-IFN-γ IgG autoantibodies.
Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfections with atypical mycobacteria are rare and sometimes difficult to correctly diagnose. In many cases underlying diseases such immune deficiency can promote these infections. CASE PRESENTATION: A 43-year-old male of Southeast Asian origin presented to our tertiary care hospital with persistent cervical lymphadenopathy non-responsive to antibiotics. Imaging suggested malignancy, but a biopsy did not confirm this suspicion. PCR diagnostics identified Mycobacterium genavense and further immunological testing revealed an acquired adult-onset immunodeficiency due to neutralizing anti-IFN-γ autoantibodies (nAIGA), explaining both the current infection and previous pleural empyema. The patient responded well to triple antimycobacterial therapy, with no recurrence or novel infection after almost two years.
conclusionsOur case highlights the importance of considering underlying immunodeficiencies and the patient's geographic origin in the diagnosis of rare infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.